Global Alzheimer's Disease Diagnostic Market – Industry Trends and Forecast to 2030

Alzheimer's Disease Diagnostic Market Analysis and Size

Alzheimer's disease diagnostics involve various techniques and methods aimed at identifying the presence of Alzheimer's disease and distinguishing it from other forms of dementia or cognitive decline. These diagnostic tools and tests include imaging techniques (such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans), genetic testing, cerebrospinal fluid analysis, and cognitive assessment tests.

Data Bridge Market Research analyses that the alzheimer's disease diagnostic market was valued at USD 10,376.30 million in 2022 and is expected to reach the value of USD 22,454.74 million by the year 2030, at a CAGR of 9.40% during the forecast period.  "Nervous System" dominates the type segment of the alzheimer's disease diagnostic market owing to the increasing awareness of albinism. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Alzheimer's Disease Diagnostic Market Scope and Segmentation

Market Definition

Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects individuals' memory, thinking, and behavior. It is the most common cause of dementia, accounting for approximately 60-70% of all dementia cases. There has been a huge rise in the number of cases of alzheimer’s disease around the globe, stressing the importance for cultivating its useful medication.

Alzheimer's Disease Diagnostic Market Dynamics

Drivers

• Increasing Prevalence of Alzheimer's Disease

The rising prevalence of Alzheimer's disease globally is a major driver for the market. As the aging population continues to grow, the number of individuals affected by Alzheimer's disease is also increasing, creating a higher demand for diagnostic tools and tests. This in turn has carved the way for the growth of the market.

• Growing Awareness and Early Diagnosis

There is an increasing awareness of the importance of early diagnosis and intervention in Alzheimer's disease. Early detection allows for better management of symptoms, access to support services, and potential participation in clinical trials, driving the demand for diagnostic tools.

• Advancements in Diagnostic Technologies

The development of advanced imaging techniques, genetic testing methods, and biomarkers has improved the accuracy and reliability of alzheimer's disease diagnosis. These advancements drive the adoption of diagnostic tools and tests in clinical practice.

Opportunity

Increasing Per Capita Expenditure

The government initiatives, schemes, or funding that support and promote the innovation and development of the alzheimer's disease diagnostic market provide growth opportunities for the market players in the forecast period of 2023 to 2030. Additionally, emerging biomarkers, penetration rate, market expansion in developing countries, integration of multiple diagnostic methods globally and increasing per capita expenditure on health care will further expand the market's growth rate in the future. 

Restraints

Limited Treatment Options

Despite the availability of medications that can temporarily alleviate symptoms, there is no cure for alzheimer's disease. The lack of definitive treatment options may impact the market's growth potential and act as a restrain for the growth of the market.

Challenges

Complex Disease Pathology

On the other hand, Alzheimer's disease has a complex pathology involving multiple factors and mechanisms. Understanding the disease progression and identifying reliable biomarkers that accurately reflect the disease state remains a challenge. Also, lack of favorable reimbursement scenario and technology penetration in the developing economies, heavy custom duty imposed on the drugs, and lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market in the forecast period of 2023-2030.

This alzheimer's disease diagnostic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the alzheimer's disease diagnostic market, contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In March 1, 2022, Quanterix, a life sciences company and Eli Lilly and Company, a pharmaceutical company announced that they have signed a collaboration agreement for the diagnosis, monitoring, and treatment of Alzheimer's disease
• In May 4, 2022, Fujirebio, a subsidiary of H.U. Group Holdings, Inc., which is a producer and supplier of in vitro diagnostics products, announced that it had received approval of its product Lumipulse G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic test for FDA marketing authorization for the assessment of Alzheimer's disease in the U.S. by the U.S. Food and Drug Administration (FDA)

Global Alzheimer's Disease Diagnostic Market Scope

The alzheimer's disease diagnostic market is segmented on the basis of type, diagnostic test, and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Nervous System
• Examination
• Genetic Testing
• Minor Mental State Examination
• Brain Imaging

Diagnostic Test

• Genetic Testing
• Positron Emission Tomography
• Electroencephalography
• Magnetic Resonance Imaging
• Computed Tomography
• Other Diagnostics
• Neurological Exam
• Mini-mental State Exam (MMSE)
• Brain Imaging
• Others

End User

• Clinics
• Hospitals
• Diagnostic Centers
• Pharmaceutical Companies
• Academic Research Center

Alzheimer's Disease Diagnostic Market Regional Analysis/Insights

The alzheimer's disease diagnostic market is analysed and market size insights and trends are provided by country, type, treatment type, end-users, and distribution channel as referenced above.

The countries covered in the alzheimer's disease diagnostic market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the alzheimer's disease diagnostic market because of the growth of the incidences of alzheimer's disease with an increase in the seniority aged population and expansion of technological developments. Furthermore, high healthcare expenses and funds by the key players in turn is expected to boost the growth of the alzheimer's disease diagnostic market in the region.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The alzheimer's disease diagnostic market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for alzheimer's disease diagnostic market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the alzheimer's disease diagnostic market. The data is available for historic period 2010-2021.

Competitive Landscape and Alzheimer's Disease Diagnostic Market Share Analysis

The alzheimer's disease diagnostic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to alzheimer's disease diagnostic market.

Some of the major players operating in the alzheimer's disease diagnostic market are:

• AbbVie (U.S.)
• AC Immune (Switzerland)
• AMARANTUS BIOSCIENCE HOLDINGS, INC. (U.S.)
• Anavex Life Sciences Corp. (U.S.)
• Eli Lilly and Company (U.S.)
• AXON Neuroscience (Slovakia)
• Sio Gene Therapies (U.S.)
• Daiichi Sankyo Company, Limited (Japan)
• F. Hoffmann-La Roche (Switzerland)
• General Electric Company (U.S.)
• Janssen Pharmaceuticals, Inc. (Belgium)
• TauRx Pharmaceuticals Ltd (Singapore)
• Alector, Inc. (U.S.)
• Accera, Inc. (U.S.)
• Treventis Corporation (Canada)
• NeuroBio (South Korea)
• Cognition Therapeutics, Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Quanterix (U.S.)

SKU-61323